Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation and Depletion: 2016-2025

Historic Depreciation and Depletion for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $3.4 million.

  • ImmunityBio's Depreciation and Depletion fell 12.82% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 13.84%. This contributed to the annual value of $15.5 million for FY2024, which is 6.06% down from last year.
  • ImmunityBio's Depreciation and Depletion amounted to $3.4 million in Q3 2025, which was down 0.00% from $3.4 million recorded in Q2 2025.
  • ImmunityBio's 5-year Depreciation and Depletion high stood at $4.6 million for Q4 2022, and its period low was $3.0 million during Q2 2021.
  • Moreover, its 3-year median value for Depreciation and Depletion was $3.9 million (2024), whereas its average is $3.8 million.
  • The largest annual percentage gain for ImmunityBio's Depreciation and Depletion in the last 5 years was 54.17% (2021), contrasted with its biggest fall of 37.93% (2021).
  • Over the past 5 years, ImmunityBio's Depreciation and Depletion (Quarterly) stood at $3.6 million in 2021, then climbed by 27.78% to $4.6 million in 2022, then dropped by 10.87% to $4.1 million in 2023, then dropped by 12.20% to $3.6 million in 2024, then fell by 12.82% to $3.4 million in 2025.
  • Its Depreciation and Depletion was $3.4 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.3 million in Q1 2025.